Know Cancer

forgot password

A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme

Phase 2
18 Years
Open (Enrolling)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor

Thank you

Trial Information

A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme


I. 6-month progression-free survival (PFS-6) measured from start of treatment following


I. Toxicity. (Clinical) II. Overall survival. (Clinical) III. Tumor response (PR+CR:
MacDonald criteria). (Clinical) IV. Determination of in vivo drug effect in recurrent GBM.
(Correlative studies) V. Determination of in vitro drug effect on CD133+ glioma-derived
neurospheres. (Correlative studies) VI. Determination of Sonic Hedgehog pathway activation
in primary vs. recurrent GBM. (Correlative studies)


I. Correlate clinical outcome (6 mo PFS) with biologic correlates (1-3) above.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive oral Hedgehog antagonist GDC-0449 once daily for 7 days before

Arm II: Patients do not receive treatment before surgery. Beginning within 28 days after
surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on
days 1-28. Courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.

Fresh and paraffin-embedded tissue samples are collected for correlative laboratory studies.

After completion of study treatment, patients are followed up every 2 months.

Inclusion Criteria:

- Patients must have histologically proven glioblastoma which is progressive or
recurrent following radiation therapy +/- chemotherapy

- Patients must have measurable contrast-enhancing progressive or recurrent
glioblastoma by MRI imaging prior to starting treatment; patient must be able to
tolerate MRIs

- Patients must be eligible for surgical resection according to the following criteria:

- Patient competent to sign consent

- Expectation that the surgeon can resect >= 50% of the Gd-enhancing tumor with
low risk of inducing neurological injury

- Lack of hematologic, cardiac or other medical contraindications to surgery

- Surgery must take place Monday-Thursday, with the exception of patients being
treated at Cleveland Clinic/University Hospitals: these patients may undergo
surgery Monday-Friday

- Patients must have a tumor size ≥ 2.5 cm in diameter in two perpendicular planes
in order to enable correlative studies

- Paraffin embedded tissue must be available from initial surgical resection at
diagnosis (prior to any treatment)

- Patients may have an unlimited number of prior therapy regimens

- Patients must have recovered from severe toxicity of prior therapy; the following
intervals from previous treatments are required to be eligible:

- 3 months from the completion of radiation

- 6 weeks from a nitrosourea chemotherapy

- 3 weeks from a non-nitrosourea chemotherapy

- 4 weeks from any investigational (not FDA-approved) agents

- 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,
tarceva, hydroxychloroquine, bevacizumab, etc.)

- Patients may be on a non-enzyme-inducing anti-epileptic drug (non-EIAED); they may
not be on an EIAED; if previously on an EIAED, patient must be off for at least 14
days prior to the first dose of GDC-0449

- Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
able to care for himself/herself with occasional help from others)

- WBC ≥ 3,000/mcL

- Absolute neutrophil count ≥ 1,500/mcL

- Platelets ≥ 100,000/mcL

- Total bilirubin ≤ institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) ≤ 4.0 X institutional upper limit of normal

- Creatinine within institutional upper limit of normal OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Patients must be able to provide written informed consent

- The effects of GDC-0449 on the developing human fetus at the recommended therapeutic
dose are unknown; for this reason and because Hh signal pathway inhibitors are known
to be teratogenic, women of child-bearing potential and men must use two forms of
contraception (i.e., barrier contraception and one other method of contraception)
prior to study entry, for the duration of study participation, and for at least 12
months post-treatment; should a woman become pregnant or suspect she is pregnant
while participating in this study, she should inform her treating physician

- Women of childbearing potential are required to have a negative serum pregnancy test
(with a sensitivity of at least 25 mIU/mL) within 10-14 days prior to treatment start
and be required to agree to have the test repeated within 24 hours prior to the first
dose of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be
administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if
their cycles are irregular while on study within the 24-hour period prior to the
administration of GDC-0449; a positive urine test must be confirmed by a serum
pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and
document the patient's use of two contraceptive methods, dates of negative pregnancy
test, and confirm the patient's understanding of the teratogenic potential of
GDC-0449; women of childbearing potential are defined as follows:

- Patients with regular menses

- Patients with amenorrhea, irregular cycles, or using a contraceptive method that
precludes withdrawal bleeding

- Women who have had a tubal ligation

- Women are considered not to be of childbearing potential for the following reasons:

- The patient has undergone hysterectomy and/or bilateral oophorectomy

- The patient is post-menopausal defined by amenorrhea for at least 1 year in a
woman > 45 years old

- Patients may not be breast-feeding a child

- Patients must have a Mini Mental State Exam score of >= 15

Exclusion Criteria:

- Patients with serious concurrent infection or medical illness, which would jeopardize
the ability of the patient to receive the treatment outlined in this protocol with
reasonable safety, are ineligible

- Patients may not be receiving any other investigational agents

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to GDC-0449 or other agents used in the study are

- Patients taking medications with narrow therapeutic indices that are metabolized by
cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) are ineligible

- GDC-0449 inhibits CYP2C8, CYP2C9, and CYP2C19 drug metabolism enzymes in vitro at
concentrations that may be clinically relevant; therefore, caution should be
exercised when dosing GDC-0449 concurrently with medications that are substrates of
CYP2C8, CYP2C9, and CYP2C19 and have narrow therapeutic windows; in addition,
GDC-0449 is a substrate of CYP3A4; however, the in vitro metabolic conversion of
GDC-0449 is low; effects of CYP inducers (e.g., carbamazepine, phenobarbital,
phenytoin, rifabutin, rifampin, St. John's wort, and troglitazone) on clinical
concentrations of GDC-0449 are unknown; likewise, the effects of strong inhibitors of
CYP3A4 (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone,
and telithromycin) on GDC-0449 clinical concentrations are unknown, and caution
should be exercised when dosing GDC-0449 concurrently with inhibitors of CYP3A4

- Patients with malabsorption syndrome or other condition that would interfere with
intestinal absorption are ineligible; patients must be able to swallow capsules

- Patients with clinically important history of liver disease, including viral or other
hepatitis or cirrhosis are ineligible

- Patients with a history of uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or
hypokalemia defined as less than the lower limit of normal for the institution,
despite adequate electrolyte supplementation are excluded from this study

- Patients with uncontrolled intercurrent illness including, but not limited to,
hypertension, ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements, are ineligible

- Pregnant women are excluded from this study because GDC-0449 is an Hh pathway
inhibiting agent with the potential for teratogenic or abortifacient effects; because
there is an unknown but potential risk for adverse events in nursing infants
secondary to treatment of the mother with GDC-0449, breastfeeding should be
discontinued if the mother is treated with GDC-0449

- HIV-positive patients on combination antiretroviral therapy are ineligible because of
the potential for pharmacokinetic interactions with GDC-0449

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival (PFS)

Outcome Description:

Estimated using Kaplan Meier curves.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Charles Nock

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Food and Drug Administration

Study ID:




Start Date:

February 2010

Completion Date:

Related Keywords:

  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Recurrent Adult Brain Tumor
  • Brain Neoplasms
  • Glioblastoma
  • Gliosarcoma



Cleveland Clinic FoundationCleveland, Ohio  44195
Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania  19104-4283
Henry Ford HospitalDetroit, Michigan  48202
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Case Western Reserve UniversityCleveland, Ohio  44106
Emory UniversityAtlanta, Georgia  30322
Wake Forest University Health SciencesWinston-Salem, North Carolina  27157
University of California San Francisco Medical Center-Mount ZionSan Francisco, California  94115
University of California at Los Angeles (UCLA )Los Angeles, California  90095
University of California San Francisco Medical Center-ParnassusSan Francisco, California  94143
Adult Brain Tumor ConsortiumBaltimore, Maryland  21231-1000